UBS analyst Ashwani Verma raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $32 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating
- ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings
- Acadia Pharmaceuticals price target raised to $24 from $23 at Mizuho
- Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion
- Acadia Pharmaceuticals price target raised to $27 from $23 at BofA